Paper Details

  1. Home
  2. Paper Details

Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.

Author: AragonaGiovanni, CavallaroLucas G, CavestroGiulia Martina, CollaGiancarlo, ComparatoGiuseppe, FanigliuloLibera, FranzéAngelo, IoriVeronica, MainoMarta, MarioFrancesco Di, MazzocchiGiancarlo, MuzzettoPierantonio, SianesiMario

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy of mesalazine for symptomatic relief of uncomplicated diverticular disease of the colon. Cyclic administration of mesalazine was effective in reducing symptoms, with mesalazine 800 mg bid showing greater improvement than other treatment schedules.
Paper Details　
Original Abstract of the Article :
In uncomplicated diverticular disease, treatment is aimed at relieving symptoms. The aim of the present study was to evaluate the efficacy of mesalazine for symptomatic relief of uncomplicated diverticular disease of the colon. Two hundred sixty-eight consecutive eligible outpatients (122 male, 146 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10620-007-9766-8

データ提供：米国国立医学図書館（NLM）

Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-Up

Diverticular disease, a common condition affecting the digestive system, can cause significant discomfort and complications. This research explores the effectiveness of mesalazine, a medication commonly used for inflammatory bowel disease, in preventing complications and symptomatic recurrences in uncomplicated diverticular disease. The study involved 268 patients with uncomplicated diverticular disease, randomly assigned to receive either rifaximin or mesalazine for 12 months. The findings suggest that cyclic administration of mesalazine, particularly at a higher dose, was effective in reducing the frequency of symptoms and preventing complications in patients with uncomplicated diverticular disease.

Mesalazine for Diverticular Disease

This research highlights the potential benefits of mesalazine for managing uncomplicated diverticular disease. The study found that patients treated with mesalazine experienced a lower frequency of symptoms, particularly those treated with a higher dose. These findings suggest that mesalazine may be a valuable therapeutic option for preventing complications and improving symptom control in patients with diverticular disease.

Managing Diverticular Disease

This research provides valuable insights for managing diverticular disease. The findings suggest that cyclic administration of mesalazine, particularly at a higher dose, may be an effective strategy for reducing symptom frequency and preventing complications. This information can help doctors make informed decisions about treatment options for patients with diverticular disease.

Dr. Camel's Conclusion

Just like a camel adapts to the arid desert environment, doctors need to find effective ways to manage the challenges posed by diverticular disease. This research suggests that mesalazine, a medication commonly used for other digestive conditions, may offer a valuable solution for preventing complications and reducing symptom frequency in patients with uncomplicated diverticular disease. This study encourages further exploration of mesalazine as a therapeutic option for managing this common condition.

Date :
  1. Date Completed 2007-11-13
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

17410435

DOI: Digital Object Identifier

10.1007/s10620-007-9766-8

Related Literature

Article Analysis
・Side Effects of barium sulfate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.